Literature DB >> 22818770

Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.

Takaaki Yamada1, Toshiharu Nonaka, Takahisa Yano, Toshio Kubota, Nobuaki Egashira, Takehiro Kawashiri, Ryozo Oishi.   

Abstract

The purpose of this study was (i) to determine the optimal dosage of teicoplanin for each patient group stratified by renal function and weight based on a population pharmacokinetic model and observed distribution of patient characteristics and (ii) to develop new simplified dosing regimens designed to achieve 15-30 μg/mL. Patient data were collected retrospectively from routine therapeutic drug monitoring files of adult patients who were given the standard loading dose regimen of teicoplanin (400 mg twice on Day 1, followed by 400 mg once daily for 2 days) and whose trough concentration was measured just before administration on Day 4. Monte Carlo simulation was conducted to estimate the trough concentration at 72 h after the initial loading dose (C(min)(72 h)) and at steady state (C(ss)(min)). The percentage of observed C(min)(72 h) in patients who received the standard loading dose regimen outside the non-parametric 90% prediction interval (from 5th to 95th percentile) of the simulated C(min)(72 h) was <10%. Simplified loading dose and maintenance dose regimens for each group stratified by renal function and weight were created to achieve C(min)(72 h) and C(ss)(min) of 15 μg/mL and 20-25 μg/mL, respectively. The percentage of C(min)(72 h) and C(ss)(min) in the range 15-30 μg/mL was 43-65% and 61-82% across each renal function and weight strata, respectively. These new simplified dosing regimens of teicoplanin could be helpful in individual adjustment of the loading and maintenance doses to achieve 15-30 μg/mL.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22818770     DOI: 10.1016/j.ijantimicag.2012.05.025

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.

Authors:  T Ueda; Y Takesue; K Nakajima; K Ichiki; A Doita; Y Wada; T Tsuchida; Y Takahashi; M Ishihara; H Ikeuchi; M Uchino; T Kimura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-09       Impact factor: 3.267

2.  Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.

Authors:  Catherine J Byrne; Jason A Roberts; Brett McWhinney; Jerome P Fennell; Philomena O'Byrne; Evelyn Deasy; Sean Egan; Ronan Desmond; Helen Enright; Sheila A Ryder; Deirdre M D'Arcy; Johnny McHugh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  Therapeutic drug concentrations of teicoplanin in clinical settings.

Authors:  So-Yun Nah; Jae Hyoung Im; Jin Yeob Yeo; Ji-Hyeon Baek; Cheol-Woo Kim; Moon-Seok Nam; Hye-Kyung Lee; Moon-Hyun Chung; Jin-Soo Lee
Journal:  Infect Chemother       Date:  2014-03-21

4.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

5.  Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions.

Authors:  Liuliu Gao; Hua Xu; Qi Ye; Sichan Li; Jun Wang; Yan Mei; Changhe Niu; Ting Kang; Chen Chen; Yang Wang
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

6.  Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

Authors:  V Ramos-Martín; M N Neely; K Padmore; M Peak; M W Beresford; M A Turner; S Paulus; J López-Herce; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.